Science

Asaf Maoz: Have You Seen Non-Response to Immunotherapy in Locally Advanced dMMR/MSI-H Rectal Cancer?

Asaf Maoz/LinkedIn

May 9, 2025, 16:45

Asaf Maoz: Have You Seen Non-Response to Immunotherapy in Locally Advanced dMMR/MSI-H Rectal Cancer?

Asaf Maoz, Medical Oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn:

“Have you seen non-response to immunotherapy in locally advanced dMMR/MSI-H rectal cancer?

We describe such a case with underlying MMR heterogeneity as a potential mechanism of resistance to dostarlimab.”

Title: Intratumoral Heterogeneity of Mismatch Repair Status and Outcome of Treatment With Dostarlimab in a Patient With Locally Advanced Rectal Adenocarcinoma

Authors: Asaf Maoz, Ronald Bleday, Jeffrey Goldsmith, Shanna A. Matalon, Mark S. Redston, Molly Nestor, NP, Jonathan A. Nowak, Matthew B. Yurgelun

You can read the Full Article on JCO Precision Oncology.

Asaf Maoz: Have You Seen Non-Response to Immunotherapy in Locally Advanced dMMR/MSI-H Rectal Cancer?

More posts featuring Dostarlimab.

Asaf Maoz cancer Dostarlimab Jeffrey Goldsmith Jonathan A Nowak Mark S. Redston Matthew B. Yurgelun Molly Nestor OncoDaily Oncology rectal adenocarcinoma rectal cancer Ronald Bleday Shanna A. Matalon

Who From Oncology is Featured in TIME100 Health 2025?

Francesco Acerbi and Testicular Cancer: The Defender's Fight and Triumphant Return to Football

Yvonne Award for Breakthrough Research 2024 Recipient to Time100 Health List

Dr Saunthari Somasundaram is the new President-Elect of the NCD Alliance

Does Plastic Cause Cancer? Myths and Facts